Search results

  1. J

    VX 809/770 Phase 2 interim results - 5-10% improvement in lung function

    From the release: <h1>'People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation'</h1>
  2. J

    VX 809/770 Phase 2 interim results - 5-10% improvement in lung function

    From the release: <h1>'People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation'</h1>
  3. J

    VX 809/770 Phase 2 interim results - 5-10% improvement in lung function

    <a href="http://investors.vrtx.com/releasedetail.cfm?ReleaseID=670755">http://investors.vrtx.com/releasedetail.cfm?ReleaseID=670755</a> <h2>Interim analysis showed 46% of patients experienced at least 5% absolute improvement in lung function (FEV1) from baseline; 30% of patients experienced at...
  4. J

    VX 809/770 Phase 2 interim results - 5-10% improvement in lung function

    <a href="http://investors.vrtx.com/releasedetail.cfm?ReleaseID=670755">http://investors.vrtx.com/releasedetail.cfm?ReleaseID=670755</a> <h2>Interim analysis showed 46% of patients experienced at least 5% absolute improvement in lung function (FEV1) from baseline; 30% of patients experienced at...
  5. J

    Information for people in Australia waiting for Kalydeco

    Thankyou for the great info GenH.
  6. J

    Information for people in Australia waiting for Kalydeco

    Thankyou for the great info GenH.
  7. J

    VX-770 to be 250K p/year per patient

    Just stumbled over this article...<br><br><A HREF="http://www.forbes.com/forbes/2011/0808/features-biotech-fred-van-goor-medicines-drug-your-own_2.html">http://www.forbes.com/forbes/2011/0808/features-biotech-fred-van-goor-medicines-drug-your-own_2.html</A><br><br>'Mark Schoenebaum, an analyst...
  8. J

    VX-770 to be 250K p/year per patient

    Just stumbled over this article...<br><br><A HREF="http://www.forbes.com/forbes/2011/0808/features-biotech-fred-van-goor-medicines-drug-your-own_2.html">http://www.forbes.com/forbes/2011/0808/features-biotech-fred-van-goor-medicines-drug-your-own_2.html</A><br><br>'Mark Schoenebaum, an analyst...
  9. J

    VX-770 to be 250K p/year per patient

    Just stumbled over this article...<br><br><A HREF="http://www.forbes.com/forbes/2011/0808/features-biotech-fred-van-goor-medicines-drug-your-own_2.html">http://www.forbes.com/forbes/2011/0808/features-biotech-fred-van-goor-medicines-drug-your-own_2.html</A><br><br>'Mark Schoenebaum, an analyst...
View older results
Top